

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.

OMB APPROVAL
OMB Number: 3235-0076
Estimated Average burden hours per response: 4.0

1. Issuer's Identity			
CIK (Filer ID Number)	Previous Name(s)	▼ None	Entity Type
0001615219			⊙ Corporation
Name of Issuer			C Limited Partnership
Flex Pharma, Inc.			
Jurisdiction of Incorporation/Organization			C Limited Liability Company C General Partnership
DELAWARE			C Business Trust
Year of Incorporation/Organiz	ation		C Other
Over Five Years Ago			
Within Last Five Years (Specify Year)	2014		
C Yet to Be Formed			
2. Principal Place of I	Business and	d Contact Inf	ormation
Name of Issuer			
Flex Pharma, Inc.			
Street Address 1		Street Address	2
800 BOYLSTON STREET		24TH FLOOR	
City	State/Province/Cou	ıntry ZIP/Postal	Code Phone No. of Issuer
BOSTON	MASSACHUSETT	S 02199	617-874-1821

3. Related Persons				
Last Name	First Name		Middle Name	
Westphal	Christoph			
Street Address 1		Street Address	2	
c/o Flex Pharma, Inc.		800 Boylston	Street, 24th Floor	
City	State/Province	ce/Country	ZIP/Postal Code	
Boston		SETTS	02199	
Relationship: Exec	utive Officer	□ Director	Promoter	
Clarification of Response (if Nec	essary)			
Last Name	First Name		Middle Name	
Hutt	Peter		Barton	
Street Address 1		Street Address	2	
c/o Flex Pharma, Inc.		800 Boylston S	800 Boylston Street, 24th Floor	
City	State/Province	ce/Country	ZIP/Postal Code	

Boston		MASSACHUS	ETTS	0219	99	
Relationship:	Execu	tive Officer	Director		Promoter	
Clarification of Respons	se (if Neces	ssary)				
Last Name		First Name		Midd	le Name	
Kraus		Stephen		7		
Street Address 1			Street Address	2		
c/o Flex Pharma, Inc.			800 Boylston	Street, 2	24th Floor	
City		State/Province	e/Country	ZIP/P	ostal Code	
Boston		MASSACHUS	ETTS	0219	02199	
			-			
Relationship:	Execu	tive Officer	Director		Promoter	
Clarification of Respons	se (if Neces	seany)				
Clarification of Respons	se (ii Neces	oodiy)				
-						
4. Industry Groυ	ıp					
C Agriculture		Health Ca		C	Retailing	
Banking & Financial	Services			0	Restaurants	
C Commercial Ban	king	2000	Insurance		Taskaslama	
C Insurance			als & Physicians aceuticals		Technology	
C Investing			Health Care		C Computers	
C Investment Bank	-	Cother	nealth Care		Telecommunications	
C Pooled Investme	ent Fund				C Other Technology	
Other Banking & C Services	Financial				Travel	
C Business Services		C Manufact	uring		C Airlines & Airports	
		Real Estat	te		C Lodging & Conventions	
Energy C Coal Mining		C Comm	ercial		C Tourism & Travel	
C Electric Utilities		C Const	ruction		C Other Travel	
C Energy Conserva	ation	C REITS	& Finance	0	Other	
C Environmental S	ervices	C Reside		3.07	Other	
C Oil & Gas		C Other	Real Estate			
C Other Energy						
5. Issuer Size						
Revenue Range			Aggregate Net	Accat V	Zalue Pange	
C No Revenues			7040		Asset Value	
C \$1 - \$1,000,000			C \$1 - \$5,000,			
\$1,000,001 - \$5,000,0	000		2000		0.000	
\$5,000,001 - \$3,000,000		\$5,000,001 - \$25,000,000 \$25,000,001 - \$50,000,000				
\$25,000,001 - \$23,000			\$25,000,001			
Over \$100,000,000	,					
© Decline to Disclose		Over \$100,000				
7.20			10901 2000		•	
Not Applicable			Not Applic	auie		

Federal Exemption(s) an apply)	nd Exclusion(s) Claimed (select all that
Rule 504(b)(1) (not (i), (ii) or (iii))	Rule 505
Rule 504 (b)(1)(i)	Rule 506(b)
Rule 504 (b)(1)(ii)	Rule 506(c)
Rule 504 (b)(1)(iii)	Securities Act Section 4(a)(5)
	☐ Investment Company Act Section 3(c)
7. Type of Filing	
New Notice Date of First Sale	2014-07-23 First Sale Yet to Occur
Amendment	
8. Duration of Offering	
Does the Issuer intend this offering to la	st more than one year? C Yes 6 No
9. Type(s) of Securities Of	fered (select all that apply)
Pooled Investment Fund Interests	Equity
Tenant-in-Common Securities	Debt
Mineral Property Securities	Option, Warrant or Other Right to Acquire Another Security
Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security	Other (describe)
10. Business Combination	Transaction
Is this offering being made in connection combination transaction, such as a mergexchange offer?	
Clarification of Response (if Necessary)	
11. Minimum Investment	
Minimum investment accepted from any outside investor	\$ 0 USD
12. Sales Compensation	
Recipient	Recipient CRD Number None
(Associated) Broker or Dealer	None (Associated) Broker or Dealer None CRD Number
Street Address 1	Street Address 2
City	State/Province/Country ZIP/Postal Code
State(s) of Solicitation	All States

13. Offering and Sales Amounts

Total Offering \$ 22000000 USD Indefinite	
Total Amount Sold \$ 16224982 USD	
Total Remaining to be Sold USD Indefinite	
Clarification of Response (if Necessary)	
	1
14. Investors	
Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, Number of such non-accredited investors who already have invested in the offering	
Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:	
15. Sales Commissions & Finders' Fees Expenses	
Provide separately the amounts of sales commissions and finders' fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.	
Sales Commissions \$ 0 USD Estimate	
Finders' Fees \$ 0 USD Estimate	
Clarification of Response (if Necessary)	
16. Use of Proceeds	
Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.	•
\$ USD Estimate	
Clarification of Response (if Necessary)	
Signature and Submission	
Olgitataro ana Gabrinolion]
Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.	
Terms of Submission	
In submitting this notice, each Issuer named above is:	

- Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*
- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against it in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
- Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Regulation D for one of the reasons stated in Rule 505(b)(2)(iii) or Rule 506(d).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
Flex Pharma, Inc.	/s/ Christoph Westphal	Christoph Westphal	President & CEO	2014-08-06